



## PWYLLGOR CRONFA ELUSENNOL CHARITABLE FUNDS COMMITTEE

<b>DYDDIAD Y CYFARFOD: DATE OF MEETING:</b>	26 September 2022
<b>TEITL YR ADRODDIAD: TITLE OF REPORT:</b>	Consideration of Charitable Funds Expenditure Requiring Committee Approval: Respiratory Research, Prince Philip Hospital
<b>CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:</b>	Sarah Perry, General Manager Unscheduled Care Andrew Carruthers, Director of Operations
<b>SWYDDOG ADRODD: REPORTING OFFICER:</b>	Anna Thomas, Service Delivery Manager Professor Keir Lewis, Respiratory Consultant

**Pwrpas yr Adroddiad (dewiswch fel yn addas)**

**Purpose of the Report (select as appropriate)**

Ar Gyfer Penderfyniad/For Decision

### ADRODDIAD SCAA

#### SBAR REPORT

##### Sefyllfa / Situation

This report is being presented to the Charitable Funds Committee to consider and approve a contribution of £10,000 (in lieu of a recent legacy donation) from the Prince Philip Hospital Respiratory Medicine charitable fund (T103) to Professor Keir Lewis's Research & Development (R&D) account (1413) as a one-off investment to support the continuation of research into lung disease, including COVID-19.

During the past 24 months, the pandemic has had a significant impact on commercial research worldwide and hindered the commercial income used to support other respiratory researchers and ongoing projects. This transfer of funding will allow time for NHS restart to continue, and hopefully regain, commercial income from various planned pharmaceutical trials, which are mainly hosted by Prince Philip Hospital (PPH), thus enabling the R&D charitable account to recover, replenish and become self-sustaining again.

##### Cefndir / Background

The Professor Lewis R&D account 1413 currently fully funds a Research Assistant Band 4 post. During 2020-21, commercial research could not be undertaken in PPH, however important COVID-19 work was undertaken. With the exception of externally funded Government trials, such as the Post- Hospitalisation COVID 19 Study and the Randomised Evaluation of COVID-19 Therapy (RECOVERY), PPH was the only site worldwide to run the following three important COVID-19 projects during these difficult times:

- ImmunoRes C19
- Continuous Positive Airway Pressure (CPAP) device trial
- Artificial Intelligence reporting of lung scans

These projects were undertaken in conjunction with a local manufacturing company, Swansea University, and new institutions such as the Ministry of Defence. The potential for job creation, partnerships and clinical benefit to participants is large. It is important to note that the success

of these projects has been due to the Research Assistant Band 4 post, which is currently instrumental in managing two portfolio research trials and supporting other activity such as the Hywel Dda COVID-19 data uploads, which contributes to a national COVID-19 report. Maintaining this post would validate its valuable contribution, unique skill set and investment in training.

The Prince Philip Hospital Respiratory Medicine charitable fund (T103) received a legacy gift of £31,142.79 on 31<sup>st</sup> March 2022, following a personal bequest and the Committee is requested to consider and approve that £10,000 of this gift is used to directly support the Band 4 post and pay for other small consumables to continue our research.

The investment will enable a greater number of patients to benefit from the life enhancing treatments that are only available through clinical trials.

### Asesiad / Assessment

#### Benefits

If successful, the funding will allow “breathing space” to maintain the post to continue the projects, including maintaining research files, blood and urine sample processing, sample shipments and additional paperwork such as the completion of adverse event forms in a timely way. Three new commercial trials have commenced, and it is anticipated that the 1413 R&D account will be replenished to its previous levels within 8 months.

#### Risks

There is a risk that the post is discontinued and account research outside of large government trials is stopped. This jeopardises staff morale, reduces staff development opportunities, stops partnerships with local industry and local academia, and will have a large impact on further commercial income generation. There will be reduced access for Hywel Dda patients into certain research studies and state of the art medications / technologies that are currently not available in routine care.

#### Funding request

£10,000 of the £31,142.79 legacy for respiratory services, specifically for respiratory research.

#### Eligibility

This request is eligible for charitable funds in line with the charity’s eligibility criteria summarised below:

Items that <u>CAN</u> be funded by charitable funds	Items <u>NOT</u> to be funded by charitable funds
<b>6. Research &amp; Development</b>	
Non-commercial medical research with direct benefits to NHS patients where ethical approval has already been granted and no other source of funding exists.	Commercial research or non-medical research.
Research where clear public/patient benefit potential is anticipated and where the results will be made publicly available. Funding will generally be limited to the balances in those funds that are raised and held specifically for purposes of research.	Research where the charity or UHB is unable to secure the intellectual property or other rights if the research is successful.

## Argymhelliad / Recommendation

The Charitable Funds Committee is requested to consider and approve the one-off contribution of £10,000 from the Prince Philip Hospital Respiratory Medicine charitable fund (T103) to the Research & Development charitable account (1413). The monies will be treated in accordance with the research and development procedures governing investigator accounts within Hywel Dda.

### **Amcanion: (rhaid cwblhau)**

#### **Objectives: (must be completed)**

Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor:	4.4 Provide assurance to the Board that all plans put forward for the approval of the Health Board for improving the local population's health and developing and delivering high-quality, safe and sustainable services to patients, and the implementation of change, are consistent with the Board's overall strategic direction and any requirements and standards set for NHS bodies in Wales.
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	Not Applicable
Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	3.1 Safe and Clinically Effective Care 3.3 Quality Improvement, Research and Innovation 1.1 Health Promotion, Protection and Improvement
Amcanion Strategol y BIP: UHB Strategic Objectives:	1. Putting people at the heart of everything we do 4. The best health and wellbeing for our individuals, families and communities 6. Sustainable use of resources
Amcanion Cynllunio Planning Objectives	2E Evidencing impact of charitable funds 3G Research and Innovation
Amcanion Llesiant BIP: UHB Well-being Objectives: <a href="#">Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019</a>	9. All HDdUHB Well-being Objectives apply

### **Gwybodaeth Ychwanegol: Further Information:**

Ar sail tystiolaeth: Evidence Base:	Incorporated within the report
Rhestr Termiau: Glossary of Terms:	Incorporated within the report
Partion / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Cronfa Elusennol: Parties / Committees consulted prior to Charitable Funds Committee:	Executive Team

<b>Effaith: (rhaid cwblhau) Impact: (must be completed)</b>	
<b>Ariannol / Gwerth am Arian: Financial / Service:</b>	No long term impacts. This is a one-off payment.
<b>Ansawdd / Gofal Claf: Quality / Patient Care:</b>	Supporting research has been world-wide and indeed a controlled study as part of improving mortality by 5%
<b>Gweithlu: Workforce:</b>	Immediate risk to current workforce, this will allow more time to secure their job from other funding streams.
<b>Risg: Risk:</b>	The risk of not spending this respiratory donation appropriately, we have not acted in good faith to the donor and there may be a reduction in future donations if we show no impact from their generosity.
<b>Cyfreithiol: Legal:</b>	None. Due HR processes are followed.
<b>Enw Da: Reputational:</b>	See Risk
<b>Gyfrinachedd: Privacy:</b>	None
<b>Cydraddoldeb: Equality:</b>	The risk of not supporting research means Hywel Dda patients do not get same access to state of the art and emergency treatments as other patients across Wales/UK. Our research metrics are currently below other Health Boards.